COLORADO SPRINGS, Colo., Aug. 22, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC: CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, is pleased to announce its sponsorship of UFCM iCare's third international medical cannabis conference taking place at the Faculty of Medicine of Strasbourg, France, on October 22, 2014. The multilingual conference brings together industry experts with other stakeholders, such as researchers, health professionals, and patients, to discuss the development of medical cannabis in Europe and North America.
"Cannabis Science is delighted to contribute to the UFCM iCare initiatives to encourage discussion and promote innovation in the medical cannabis arena as the Company strives to move forward in bringing cannabinoid-based medicines to patients on a global basis," said Dorothy H. Bray, Ph.D., Director, President and CEO of Cannabis Science, Inc.
French law provides for a regulatory framework for the research and development of cannabinoid-based medicine that will then be available to patients in mainstream pharmacies. The upcoming conference of international experts is intended to facilitate patient-driven dialog with the researchers and with the industry. UFCM has assembled a team of prominent speakers including Professor Raphael Mechoulam from the Hebrew University in Jerusalem in Israel and Professor Jerome Sèze from Department of Neurology, University Hospital of Strasbourg in France. Additional information about the conference and its speakers may be found here UFCM iCare Conference Speakers.
About the UFCM
Founded in 2009, the UFCM is the leading medical cannabis charity in France. Its mission is to promote medical cannabis by developing a network of doctors, patients and lawyers in France, organizing the primary French conference about medical cannabis, and providing information about medical cannabis in French. UFCM iCare Website.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Robert Kane, CFO & Director
Cannabis Science, Inc.
Raymond C. Dabney, Management Consultant, Co-Founder
SOURCE Cannabis Science, Inc.